Molecular Hematopathology Series (MSH) 2026

Occurs weekly every Monday and Wednesday starting on 1/5/2026 at 5:00 PM
Monday, January 5, 2026, 5:00 PM - 6:00 PM, Zoom, New York, NY


Leukemia Tumor Board is a structured, multidisciplinary forum in which specialists in hematology, oncology, pathology, radiology, pharmacy, and supportive care collaboratively review and discuss complex leukemia cases. The goal of the board is to integrate current evidence, clinical guidelines, and specialty expertise to refine diagnoses, evaluate therapeutic options, and develop comprehensive, patient-centered management plans. This coordinated, evidence-based approach supports high-quality care and advances clinician learning through shared decision-making and peer-to-peer education.

1. Participants will enhance their ability to apply multidisciplinary, evidence-based principles to the diagnosis and management of leukemia, integrating current guidelines and expert perspectives to support more consistent, informed clinical decision-making.
2. Clinical staff will more consistently incorporate multidisciplinary recommendations, up-to-date clinical guidelines, and coordinated care processes into their routine management of leukemia patients, resulting in more standardized and efficient delivery of care.
3. Participants will improve their ability to recognize when complex leukemia cases warrant multidisciplinary input and will more effectively synthesize diagnostic information, treatment options, and evolving best practices to guide patient care.

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (1.00 hours), ABS CC (1.00 hours), Non-Physician Attendance (1.00 hours)

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Mitigation of Relevant Financial Relationships

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all accredited CE educational activities. All individuals in control of content of an activity accredited by ISMMS are expected to disclose all their financial relationships with ineligible companies existing within the prior 24 months. All relevant financial relationships have been mitigated and disclosed to learners before the activity takes place. 

Date	Empty Column	Title
3/18/2026 8:00:00 AM	Molecular Hematopathology Multiple Myeloma Tumor Board (MSH) - 3/18/2026 3/18/2026 8:00:00 AM 3/18/2026 9:00:00 AM 15 False MM/DD/YYYY	Molecular Hematopathology Multiple Myeloma Tumor Board (MSH) - 3/18/2026 Leukemia Tumor Board is a structured, multidisciplinary forum in which specialists in hematology, oncology, pathology, radiology, pharmacy, and supportive care collaboratively review and discuss complex leukemia cases. The goal of the board is to integrate current evidence, clinical guidelines, and specialty expertise to refine diagnoses, evaluate therapeutic options, and develop comprehensive, patient-centered management plans. This coordinated, evidence-based approach supports high-quality care and advances clinician learning through shared decision-making and peer-to-peer education. Specialties: Hematology, Oncology